Misfolding company Congruence returns to the well for $39.5M round: Venture Report

Montreal-based Congruence announced its second venture round in seven months Thursday, along with the start of its first clinical trial of a treatment for genetically-driven obesity.

First-time investor Dimension and returning backer OrbiMed Advisors co-led the $39.5 million round for Congruence Therapeutics Inc., which followed the biotech’s $32 million round in September 2025. Congruence is advancing programs from its computational platform to identify and correct mutations associated with protein misfolding disorders...